Moreover, numbers of CD226+CD8+ TILs in pre-treatment tumor biopsies of melanoma patients are associated with improved progression-free survival following single anti-PD-1 therapy or anti-PD-1/anti-CTLA4 co-blockade (38). Here, CD226 is linked to melanoma.